Jaguar Health shares surge 100.13% after-hours after Napo secures $18M licensing deal for Mytesi and Canalevia with Woodward Specialty.

Jaguar Health Inc. (NASDAQ: JAGX) surged 100.13% in after-hours trading following the announcement of a licensing agreement between its subsidiary, Napo Pharmaceuticals, and Woodward Specialty. The deal grants the latter exclusive U.S. commercialization rights for Mytesi and Canalevia-CA1, with an upfront payment of $16 million and an additional $2 million contingent on future milestones. Napo retains a buy-back option after five years if new FDA approvals are secured. The agreement also includes a manufacturing and supply pact, ensuring continued U.S. production of Mytesi. This strategic partnership, combined with potential future milestone payments of up to $17 million, directly drove the stock’s sharp rise, reflecting renewed investor confidence in Jaguar Health’s financial prospects and pipeline development.